Renown Health, Gilead partner to analyze genetic, EHR data for drug discovery

Reno, Nev.-based Renown Health's Institute for Health Innovation and Foster City, Calif.-based Gilead Sciences have joined forces to develop a better understanding of and potential treatments for nonalcoholic steatohepatitis (NASH).

In the partnership, Gilead will fund Renown's efforts to sequence and analyze the DNA of 15,000 patients with NASH or nonalcoholic fatty liver disease, plus a control group of 40,000 more Nevada residents. If critical genetic variants are identified during this process, they will be shared with patients to inform their care, according to Anthony Slonim, MD, Renown's president and CEO.

The genetic analysis will be combined with EHR data from Renown's more than 1 million patients to illustrate how genetics and environmental factors affect the development of NASH, and "thereby advance the discovery and development of new treatments for this disease," said John McHutchison, MD, Gilead's chief scientific officer and head of research and development.

More articles about health IT:
Prisma Health, Clemson launch health innovation funding program
Essentia Health alerts 1,000 patients of data breach
Lab-testing startup uBiome lays off half of global workforce

© Copyright ASC COMMUNICATIONS 2019. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.

 

Top 40 Articles from the Past 6 Months